文献速递脑血管病

卵圆孔未闭封堵术与药物治疗在隐源性卒中或短暂性脑缺血发作患者中的比较:更新系统评价与荟萃分析

Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis.
PubMed 文献 · Stroke · 2018-01-15

该系统评价与荟萃分析纳入5项随机试验共3627例隐源性卒中/TIA合并PFO患者,平均随访3.7年。与药物治疗相比,PFO封堵显著降低缺血性卒中复发(0.53 vs 1.1/100患者年,OR 0.43,95%CI 0.21-0.90),但新发房颤更常见(1.3 vs 0.25/100患者年,OR 5.15,95%CI 2.18-12.15),多数在45天内缓解。TIA、全因死亡和心肌梗死无显著差异。

要点

  • PFO封堵降低缺血性卒中复发(OR 0.43),每46.5例治疗3.7年预防1例事件。
  • 新发房颤在封堵组更常见(OR 5.15),但72%在45天内缓解。
  • TIA、全因死亡和心肌梗死发生率两组无显著差异。

核心结论

  • 在隐源性卒中/TIA合并PFO患者中,PFO封堵较药物治疗降低缺血性卒中复发,但增加新发房颤风险,后者多为短暂性。

研究设计与样本

  • 检索PubMed截至2017年9月24日,纳入5项比较PFO封堵与药物治疗的随机试验,共3627例患者,平均随访3.7年。

主要发现

  • 缺血性卒中复发率封堵组0.53/100患者年 vs 药物组1.1/100患者年(OR 0.43,95%CI 0.21-0.90),相对风险降低50.5%,绝对风险降低2.11%。
  • TIA发生率0.78 vs 0.98/100患者年(OR 0.80,95%CI 0.53-1.19),无显著差异。
  • 全因死亡率0.18 vs 0.23/100患者年(OR 0.73,95%CI 0.34-1.56),无显著差异。
  • 新发房颤发生率封堵组1.3 vs 药物组0.25/100患者年(OR 5.15,95%CI 2.18-12.15),72%在45天内缓解。
  • 心肌梗死(OR 1.22,95%CI 0.25-5.91)和严重不良事件(OR 1.07,95%CI 0.92-1.25)两组相似。

关键数值与推荐

  • 预防1例缺血性卒中需治疗46.5例患者3.7年(NNT 46.5)。

临床怎么用

  • 对于隐源性卒中/TIA合并PFO的患者,可考虑PFO封堵以降低缺血性卒中复发风险,但需权衡新发房颤风险,术后应监测房颤。

局限性

  • 未报告各试验的异质性、偏倚风险及封堵器械类型等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Previous systematic reviews and meta-analyses compared the efficacy and safety of patent foramen ovale (PFO) closure versus medical treatment in patients with cryptogenic stroke or transient ischemic attack (TIA). Recently, new evidence from randomized trials became available. METHODS: We searched PubMed until September 24, 2017, for trials comparing PFO closure with medical treatment in patients with cryptogenic stroke/TIA using the items: stroke or cerebrovascular accident or TIA and patent foramen ovale or paradoxical embolism and trial or study. RESULTS: Among 851 identified articles, 5 were eligible. In 3627 patients with 3.7-year mean follow-up, there was significant difference in ischemic stroke recurrence (0.53 versus 1.1 per 100 patient-years, respectively; odds ratio [OR], 0.43; 95% confidence intervals (CI), 0.21-0.90; relative risk reduction, 50.5%; absolute risk reduction, 2.11%; and number needed to treat to prevent 1 event, 46.5 for 3.7 years). There was no significant difference in TIAs (0.78 versus 0.98 per 100 patient-years, respectively; OR, 0.80; 95% CI, 0.53-1.19) and all-cause mortality (0.18 versus 0.23 per 100 patient-years, respectively; OR, 0.73; 95% CI, 0.34-1.56). New-onset atrial fibrillation occurred more frequently in the PFO closure arm (1.3 versus 0.25 per 100 patient-years, respectively; OR, 5.15; 95% CI, 2.18-12.15) and resolved in 72% of cases within 45 days, whereas rates of myocardial infarction (0.12 versus 0.09 per 100 patient-years, respectively; OR, 1.22; 95% CI, 0.25-5.91) and any serious adverse events (7.3 versus 7.3 per 100 patient-years, respectively; OR, 1.07; 95% CI, 0.92-1.25) were similar. CONCLUSIONS: In patients with cryptogenic stroke/TIA and PFO who have their PFO closed, ischemic stroke recurrence is less frequent compared with patients receiving medical treatment. Atrial fibrillation is more frequent but mostly transient. There is no difference in TIA, all-cause mortality, or myocardial infarction.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Ntaios G, Papavasileiou V, Sagris D, et al. Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack: Updated Systematic Review and Meta-Analysis. Stroke. 2018. PMID: 29335335. doi:10.1161/STROKEAHA.117.020030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。